“Neuroendocrine Tumor Grade 3 (NET G3)” of the Uterine Cervix

Objective: To evaluate the clinical accuracy of Hepika test to identify cancer/precancerous lesions of the uterine cervix. Materials and Methods: A multicentre retrospective study was carried out in 2018 and included 330 liquid-based cytology samples from three Italian centres of women aged 25–64 who had been tested for the human papillomavirus (HPV) and whose histology or follow-up outcome was known. Hepika is an enzyme-linked immunosorbent assay (ELISA) targeting the protein complexes E6#p53 and E7#pRb. After excluding samples without sufficient residual material, the clinical accuracy of Hepika test was evaluated in 274 samples: adenocarcinoma (ADC) (4), squamous cell carcinoma (SCC) (7), adenocarcinoma in situ (AIS) (1), cervical intraepithelial neoplasia (CIN) grade 3 (60), CIN2 (51), CIN1 (34), and negative histology (117). Association, sensitivity, and specificity for carcinoma, CIN3+ and CIN2+ are reported. Results: Positive Hepika test was associated with a high probability of carcinoma (odds ratio (DOR) = 33.68, 95% confidence interval (CI) 7.0–163.1); sensitivity was 81.8%, specificity, 88.2%. A positive Hepika test showed a weaker association with CIN3+ lesions (DOR = 3.5; 95% CI 1.75–6.99) and lower sensitivity (27.8%). Conclusion: The Hepika test was found to be an accurate biomarker for HPV-induced cervical carcinoma. Population-based prospective studies are needed to confirm the clinical usefulness of the Hepika test in the differential diagnosis of HPV-induced invasive lesions.

Download Full-text

1169P First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1382 ◽

2020 ◽

Vol 31 ◽

pp. S776

Author(s):

G. Lamberti ◽

S. Pusceddu ◽

T. Ibrahim ◽

A. Bongiovanni ◽

R. Berardi ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

First Line ◽

Net G3 ◽

Well Differentiated ◽

Grade 3

Download Full-text

Multiple Hemorrhagic Brain Metastasis from a Neuroendocrine Tumor Grade 1

International Journal of Surgery Case Reports ◽

10.1016/j.ijscr.2021.105855 ◽

2021 ◽

pp. 105855

Author(s):

Turki Elarjani ◽

Othman Bin Alamer ◽

Mohammad Dababo ◽

Maher Hassounah

Keyword(s):

Brain Metastasis ◽

Neuroendocrine Tumor ◽

Tumor Grade

Download Full-text

Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors

Endocrine Related Cancer ◽

10.1530/erc-21-0051 ◽

2021 ◽

Author(s):

Marc Diedisheim ◽

Solène Dermine ◽

Anne Jouinot ◽

Amandine Septier ◽

Sébastien Gaujoux ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Pancreatic Beta Cell ◽

Tumor Biology ◽

Disease Free Survival ◽

Tumor Grade ◽

Pancreatic Alpha Cell ◽

Liver Gene ◽

Well Differentiated ◽

Grade 3 ◽

Definition Of

Duodenopancreatic neuroendocrine tumors (DPNETs) aggressiveness is heterogeneous. Tumor grade and extension are commonly used for prognostic determination. Yet, grade classes are empirically defined, with regular up-dates changing the definition of classes. Genomic screening may provide more objective classes, and reflect tumor biology. The aim of this study was to provide a transcriptome classification of DPNETs. We included 66 DPNETs, covering the entire clinical spectrum of the disease in terms of secretion, grade, and stage. Three distinct molecular groups were identified, associated with distinct outcome (log-rank p<0.01): (i) better-outcome DPNETs with pancreatic beta-cell signature. This group was mainly composed of well-differentiated, grade 1 insulinomas; (ii) poor-outcome DPNETs with pancreatic alpha-cell and hepatic signature. This group included all neuroendocrine carcinomas and grade 3 DPNETs, but also some grade 1 and grade 2 DPNETs; and (iii) intermediate-outcome DPNETs with pancreatic exocrine and progenitor signature. This group included grade 1 and grade 2 DPNETs, with some insulinomas. Fibrinogen gene FGA expression was one of the top most expressed liver gene. FGA expression was associated with disease-free survival (HR=1.13, p=0.005), and could be validated on two independent cohorts. This original pathophysiologic insight provides new prognostic classification perspectives.

Download Full-text

Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor

The Korean Journal of Pancreas and Biliary Tract ◽

10.15279/kpba.2021.26.1.24 ◽

2021 ◽

Vol 26 (1) ◽

pp. 24-32

Author(s):

Min Je Sung ◽

Moon Jae Chung

Keyword(s):

Cell Proliferation ◽

Medical Treatment ◽

Neuroendocrine Tumor ◽

Standard Treatment ◽

Pancreatic Neuroendocrine Tumor ◽

Somatostatin Analogues ◽

Proliferation Index ◽

Ki 67 ◽

Grade 3 ◽

Cell Proliferation Index

Pancreatic neuroendocrine tumor (PNET) refer to tumors originating from the islet of Langerhans and shows various prognosis based on the presence or absence of symptoms due to hormone secretion, the Ki-67 cell proliferation index, and the histologic grade, and according to the degree of disease progression defined by the tumor-node-metastasis (TNM) stage classification. The purpose of medical treatment for PNET is to control symptoms or inhibit tumor growth. Somatostatin analogues can be administered for the purpose of controlling symptoms caused by the secretion of specific hormones, and are accepted as effective drugs for inhibiting the progression of G1/G2 tumors based on World Health Organization (WHO) classification with a Ki-67 cell proliferation index less than 20%. Among the molecularly targeted agents, everolimus and sunitinib can be considered in patients with WHO G1/G2 PNET showing progression after somatostatin analog therapy. Cytotoxic chemotherapy is generally administered to patients with large tumor volume and rapidly progressing metastatic NET, and etoposide/cisplatin combination therapy has been considered as a standard treatment. For the patient group of Grade 3 PNET (well differentiated) newly classified by the WHO 2017 classification, guidelines for standard treatment have not yet been established. As it has been reported, studies are needed to evaluate the treatment response rate of somatostatin analogues or molecularly targeted therapies for the patient with Grade 3 PNET. It is important to consider a multidisciplinary approach with all possible treatment options including medical treatment, radical resection of primary or metastatic lesions, liver-directed therapies, and peptide receptor radionuclide therapy for the patients with PNET.

Download Full-text

Giant Primary Neuroendocrine Neoplasms of the Liver: Report of 2 Cases With Molecular Characterization

International Journal of Surgical Pathology ◽

10.1177/1066896919855764 ◽

2019 ◽

Vol 27 (8) ◽

pp. 893-899

Author(s):

Laura G. Pastrián ◽

Ignacio Ruz-Caracuel ◽

Raul S. Gonzalez

Keyword(s):

World Health Organization ◽

Neuroendocrine Tumor ◽

Large Cell ◽

The Other ◽

World Health ◽

Neuroendocrine Neoplasms ◽

Molecular Testing ◽

Well Differentiated ◽

Grade 3 ◽

Health Organization

Primary neuroendocrine neoplasms of the liver have occasionally been reported in the liver, though many reports do not convincingly exclude metastases. In this article, we report 2 “giant” hepatic neuroendocrine lesions without evidence of a primary elsewhere after clinical workup. One occurred in a 21-year-old male; the lesion was a large cell neuroendocrine carcinoma measuring 24 cm. The patient died of disease in 10 months. The other occurred in a 25-year-old patient, was 18 cm wide, and was diagnosed as a well-differentiated neuroendocrine tumor, World Health Organization grade 3. The patient died of disease after 30 months. Molecular testing demonstrated only the presence of TP53 mutations in common. These cases expand our knowledge of seemingly primary neuroendocrine neoplasms of the liver, in particular, giant cases measuring more than 8 cm. Guidelines for clinical workup and therapy for these lesions remain unclear, but future thorough workup of such cases is necessary for specific characterization.

Download Full-text